GLPwatch
Papers (10588)
Page 171 of 177, ranked by citation count.
- Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes.
- The Role of Glucagon-like Peptide 1 Receptor Modulators for the Management of Dumping Syndrome in Patients Who have Undergone Metabolic and Bariatric Surgery: a Scoping Review.
- Psychosocial Outcomes in Telemedicine and Long-Acting Incretin-Specific Behavioral Intervention.
- Clinical factors influencing the systolic blood pressure benefits of once-weekly semaglutide in patients with type 2 diabetes.
- A Short-Term Cost-Effectiveness Analysis of Tirzepatide Versus Semaglutide for the Treatment of Obesity in Greece.
- Retrospective chart review on psychiatric manifestations of GLP-1 agonist usage.
- [Liraglutide in polycystic ovary syndrome].
- Tirzepatide and semaglutide: different twins?
- Effect of Liraglutide combined with Jinlida granules on glycolipid metabolism and islet function of type 2 diabetes mellitus.
- Calories to satiation-A new predictor of anti-obesity therapy outcome?
- Development of a Follow-Up Protocol for Patients Treated with Injectable Semaglutide for Weight Loss: Design of a Research Study in Community Pharmacy.
- Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.
- Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications-A Narrative Review.
- Implementation of the IWQOL-Lite-CT in Observational Research: Comparison of Baseline Scores With a Clinical Trial Population and Psychometric Evaluation.
- Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
- [Effects of exendin-4 on extracellular matrix metabolism in human mesangial cells cultured in high glucose].
- Discovery of Small-Molecule GLP‑1 Receptor Agonists with Improved Oral Pharmacokinetics Based on Orforglipron.
- Effects of semaglutide, a GLP-1 receptor agonist, on food preferences in Japanese subjects with type 2 diabetes and visceral fat accumulation.
- GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.
- The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms.
- Semaglutide attenuates neuroinflammation in male mice.
- Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy.
- <sup>68</sup>Ga-labeled exendin-4 to image cardiac repair after myocardial infarction: From lizard venom to laboratory and beyond.
- Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice.
- Weight-Lowering Drugs and Natural Female Fertility-A Systematic Review and Meta-Analysis.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
- Use of semaglutide and tirzepatide among people with multiple sclerosis.
- Saxagliptin Combined with Liraglutide vs. Saxagliptin Alone on Microinflammation and Adipokines in Obese T2DM Patients with Poor Metformin Response.
- LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial.
- Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- Systemic Pharmacokinetic Principles of Therapeutic Peptides.
- Antihyperglycemic medications for cardiovascular disease risk reduction.
- Metabolic Benefits vs. Cardiovascular Uncertainty: A Critical Review of GLP-1 Receptor Agonists in Type 1 Diabetes.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy.
- Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes.
- [The Preliminary Investigation of GLP-1 Receptor Agonist on Liver Steatosis in Obese Mice].
- Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.
- Effects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review.
- Summary for Patients: Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes.
- "Ozempic Limb": Understanding the Impact of Semaglutide on Prosthesis Use and Residual Limb Care in Individuals With Lower Limb Amputation.
- Effect of Weight-Neutral Treatment With Semaglutide or Tirzepatide on β-Cell Identity in db/db Mice.
- Integrative proteogenomic analyses implicate KLK13 as a glycaemia-linked circulating protein in diabetic kidney disease.
- Phyllanthus niruri niosomes ameliorate obesity-induced hepatic steatosis in rats via modulating MALAT1/miR-206/GLP-1R signaling and hepatic lipid metabolism.
- Late-stage generation of <sup>14</sup>C/<sup>3</sup>H-radiolabeled lysine residues via hydroformylation of peptides.
- Liraglutide-mediated protection against ethanol-induced gastric ulcer in male and female rats: enhancement of mucosal defense, anti-inflammatory and antioxidant mechanism.
- In type 2 diabetes, tirzepatide reduced HbA<sub>1c</sub> vs. semaglutide.
- Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy.
- TikTokfluence: The rise of GLP-1 receptor agonists in the age of social media health trends.
- [Progress on tirzepatide, a GIP/GLP-1 receptor agonist, for the treatment of obesity-related obstructive sleep apnea].
- Benchmarking the medication efficiency and technological progress of diabetes drugs.
- The role of vasopressin deficiency in the fluid intake suppression hyper-responsivity to central glucagon-like peptide-1 in the Brattleboro rat.
- Type 2 Diabetes in Pregnancy: Management and Novel Therapies.
- Aggregation-driven expression of liraglutide precursors using engineered mini-tags in Escherichia coli.
- Childhood Obesity, Medications, and Surgeries.
- Cycling GLP-1 receptor agonist treatment induces therapeutic resistance and increased adiposity.
- [New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose].
- The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review.
- A Bibliometric Analysis Review of the Top 50 Most Cited Articles on Incretin-Based Therapy for Weight Reduction and Diabetes Management.
- Insulin therapy DE-intensificAtion with iGlarLixi: A phase 4, open-label, parallel-group randomised controlled trial.